Long-term safety of the tafenoquine antimalarial chemoprophylaxis regimen: A 12-month, randomized, double-blind, placebo-controlled trial

Anne Novitt-Moreno, Adam Martidis,Victor Gonzalez,Janet Ransom, Charles B Scott,Geoffrey Dow,Mark Reid,Bryan Smith,Victor E Zottig,Lisa Thomas Read, Lindsey S Garver Baldwin,Fred K Chen

Travel Medicine and Infectious Disease（2022）

引用 6|浏览5

暂无评分

摘要

•AE rate of tafenoquine 200 mg weekly for 52 weeks is comparable to placebo•Safety of tafenoquine at ≤12 months is comparable to prior studies of ≤6 months•Tafenoquine-induced changes in safety/laboratory parameters are mild and reversible•Tafenoquine induces reversible cornea verticillata without retinal/vision changes•Tafenoquine does not increase the risk of neuropsychiatric events vs placebo

查看译文

关键词

Tafenoquine,Malaria,Toxicity,Neuropsychiatric,Cornea,Ophthalmic

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要